COMMUNIQUÉS West-GlobeNewswire

-
Tetra Bio-Pharma Convenes First National Medical Advisory Board
04/12/2018 -
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
04/12/2018 -
Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System
04/12/2018 -
Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.
04/12/2018 -
Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
04/12/2018 -
RavenQuest Begins Cannabis Sales
04/12/2018 -
INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy
04/12/2018 -
Transactions in relation to share buyback program
04/12/2018 -
Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development
04/12/2018 -
Rule 2.9 Announcement
04/12/2018 -
Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China
04/12/2018 -
Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies
04/12/2018 -
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
04/12/2018 -
Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
04/12/2018 -
Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia
04/12/2018 -
Driven Inc. to Present at the 11th Annual LD Micro Main Event
04/12/2018 -
REVA Announces First Implant of the Fantom Encore Bioresorbable Scaffold in Italy
04/12/2018 -
Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting
04/12/2018 -
National Rheumatology and Psoriasis Organizations Release Joint Guideline for Treating Psoriatic Arthritis
03/12/2018
Pages